1 | P a g e

Objective of the study

The main objectives of the study are -

To present an overview of Beximco Pharmaceuticals Limited

To appraise the company‟s Dividend Policy

To analyze the relationship between dividend policy and market price of share.

To identify the problems

To suggest for reform

The objectives of this report is to make readers know about Beximco Pharmaceuticals

Limited and to provide information about its Dividend Policy

Scope and Methodology of the study

The report was mainly done by making some analytical approach. We have mainly used

derived/secondary data for the report. For this, we used the annual report, Dhaka Stock

Exchange website and company‟s website. For the accomplishment of our report‟s purpose, we

had chosen Beximco Pharmaceuticals Limited five year annual reports (FY 2010-2014). The

existing guiding principle, documents and other supporting papers important to this task were

also consulted and examined.

Origin of the report

Professor Dr. Tanbir Ahmed Chowdhury, Dean of Faculty of Business and Economics, East West

University as a course instructor of Corporate Finance (FIN 507) made us carry out the

accountability of preparing a report on “An appraisal of the dividend policy” by assigning it

during the mid part of this semester (Summer 2015) dated on 23/6/2015. We select Beximco

Pharmaceuticals Limited for the assignment. This report is required as a part of fulfilling the

objective of the course.

2 | P a g e

Limitation of the study

We try our best to make the report informative, error free and realistic. However, we could not

avoid some limitations, for which there might be some factual error in this report. Time

limitation is a major issue for the study work. Some limitations are as follows-

Time limitation is a major issue for the study work.

It may not be feasible to contact with investor to collect information or to have conversation

with them about dividend policy.

It will be harder to collect various data, books and journals related to the topic due to limited

accessibility of resources.

Many up-to-date data and documents may not be obtainable, which could have made the

study more informative. So a major constraint of the study will be the inadequate information.

Confidentiality of data was another barrier that was confronted during the conduct of the

study.

Our experience was very poor in comparison with the scope of study.

3 | P a g e

Beximco Pharmaceuticals Limited (Beximco Pharma) is a leading manufacturer and exporter of

medicines in Bangladesh. Incorporated in the late 70s, Beximco Pharma has begin as a

distributor, importing products from global MNCs like Bayer, Germany, USA and selling them in

the local market, which were later manufactured and distributed under licensing arrangement.

Since then, the journey continued and today, Beximco Pharma is one of the largest exporters of

medicines in Bangladesh, winning National Export (Gold) Trophy, a record four times.

The company continues to adhere to the global standards and its manufacturing facilities have

been already certified by the regulatory authorities of Europe, Australia, Canada, Latin America

and South Africa. Over the last three decades Beximco Pharma has grown from strength to

strength but the simple principle on which it was founded remains the same “Producing high

quality generics and making them affordable”. Ensuring access to quality medicines is the

powerful aspiration that motivates more than 3,000 employees of the company and each of

them is guided by the same moral and social responsibilities the company values most.

Corporate Vision

We will be one of the most trusted, admired and successful pharmaceutical companies in the

region with a focus on strengthening research and development capabilities, creating

partnerships and building presence across the globe.

Corporate Mission

We are committed to enhancing human health and well-being by providing contemporary and

affordable medicines, manufactured in full compliance with global quality standards. We

continually strive to improve our core capabilities to address the unmet medical needs of the

patients and to deliver outstanding results for our shareholders.

Core Values

Beximco Pharmaceuticals Limited has the following cores values define who are they and what guide them to take decisions and help realize their individual and corporate aspirations.

- Commitment to quality

- Customer satisfaction

- People focus

- Accountability

- Corporate social responsibility

An overview of Beximco Pharmaceuticals Limited

4 | P a g e

Achievements and Recognitions:

Year Achievements and Recognitions

2014 First Bangladeshi company to receive GMP approval from Health Canada and

Taiwan Food and Drug Administration (TFDA)

2013 First Bangladeshi company to export ophthalmic products to Europe

2012 First Bangladeshi company to launch Salbutamol GFA inhaler (Azmasol) in

Singapore

2011 Received GMP accreditation from AGES, Austria: only pharmaceutical company

to win „National Export Trophy (Gold)‟ for the fourth time

2010 The only pharmaceutical company in Bangladesh to enter the US market

through acquisition of an Abbreviated New Drug Application (ANDA)

2009 Only Bangladeshi company to receive GMP approval from ANVISA, Brazil.

2008 First Bangladeshi Company to receive GMP accreditation from Therapeutic

Goods Administration (TGA), Australia and Gulf Central Committee for Drug

Registration, for GCC states.

2006 Launched CFC free HFA inhalers for the first time in Bangladesh.

Products Category

Allergic Disorders Analgesics & Antipyretic

Analgesics & Antipyretic

Anti–infective

Cardiovascular

Central Nervous System

Cough & Cold

Endocrine & Diabetes

Eye Care

Gastrointestinal

Intravenous Fluids

Musculoskeletal

Oncology

Respiratory

Vitamins & Minerals Supplement

Skin Care & Other Products

5 | P a g e